https://s.phonesites.com/v0/b/phonesites-prod.appspot.com/o/images%2FvcSY0ZKVJYNMFEOd9pilZ7dEb7g1%2F1722097621187*nicole-lamberson-image-09*jpg?alt=media&token=7e258d93-248b-4a16-8c5b-d3550033eccb

Nicole Lamberson, PA-C, is a licensed Physician Assistant with a distinguished educational background. She earned her Bachelor of Science degree from James Madison University in 2000, followed by a Master of Physician Assistant Studies from Eastern Virginia Medical School in 2004.

Ms. Lamberson's professional career began in Urgent Care and Occupational Medicine. However, her trajectory was significantly altered by personal health challenges related to benzodiazepine use.

In 2005, Ms. Lamberson was prescribed Xanax for work-related stress. Over the subsequent five years, she experienced symptoms consistent with benzodiazepine tolerance withdrawal, which were initially misdiagnosed, leading to polypharmacy. A fortuitous encounter with a journalist's article in 2010 prompted Ms. Lamberson to investigate the connection between her symptoms and her prescribed medication, ultimately leading to her decision to discontinue use.

Following a challenging withdrawal experience, Ms. Lamberson has dedicated herself to benzodiazepine awareness and education. She contributes to several initiatives, including the Benzodiazepine Information Coalition and the Benzodiazepine Action Work Group of the Colorado Consortium. Ms. Lamberson co-founded The Withdrawal Project and is involved in marketing and outreach for "Medicating Normal - The Film." She is also an associate at the International Institute for Psychiatric Drug Withdrawal.

Ms. Lamberson's advocacy extends to her role on the American Society of Addiction Medicine's patient panel, advising on the development of FDA clinical practice guidelines for safe benzodiazepine tapering. Her contributions to The Maudsley Deprescribing Guidelines have been acknowledged, further cementing her expertise in this field.

Through her lived experience and professional background, Ms. Lamberson continues to advocate for increased education and awareness regarding benzodiazepine risks and improved prescribing and withdrawal practices.

Content